-
Je něco špatně v tomto záznamu ?
DIPG-like MYB-altered diffuse astrocytoma with durable response to intensive chemotherapy
K. Trkova, D. Sumerauer, L. Krskova, A. Vicha, M. Koblizek, T. Votava, V. Priban, M. Zapotocky
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
Grantová podpora
204220
Grantová Agentura, Univerzita Karlova
PRIMUS/19/MED/06
Grantová Agentura, Univerzita Karlova
LX22NPO5102
The project National Institute for Cancer Research (Programme EXCELES)
MH CZ-DRO,00064203
University Hospital Motol
- MeSH
- astrocytom * diagnostické zobrazování farmakoterapie genetika MeSH
- gliom * diagnostické zobrazování farmakoterapie genetika MeSH
- histony genetika MeSH
- kojenec MeSH
- lidé MeSH
- nádory mozkového kmene * diagnostické zobrazování farmakoterapie genetika MeSH
- pons patologie MeSH
- Check Tag
- kojenec MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Pontine gliomas represent difficult to treat entity due to the location and heterogeneous biology varying from indolent low-grade gliomas to aggressive diffuse intrinsic pontine glioma (DIPG). Making the correct tumor diagnosis in the pontine location is thus critical. Here, we report a case study of a 14-month-old patient initially diagnosed as histone H3 wild-type DIPG. Due to the low age of the patient, the MRI appearance of DIPG, and anaplastic astrocytoma histology, intensive chemotherapy based on the HIT-SKK protocol with vinblastine maintenance chemotherapy was administered. Rapid clinical improvement and radiological regression of the tumor were observed with nearly complete remission with durable effect and excellent clinical condition more than 6.5 years after diagnosis. Based on this unexpected therapeutic outcome, genome-wide DNA methylation array was employed and the sample was classified into the methylation class "Low-grade glioma, MYB(L1) altered." Additionally, RT-PCR revealed the presence of MYB::QKI fusion. Taken together, the histopathological classification, molecular-genetic and epigenetic features, clinical behavior, and pontine location have led us to reclassify the tumor as a pontine MYB-altered glioma. Our case demonstrates that more intensive chemotherapy can achieve long-term clinical effect in the treatment of MYB-altered pontine gliomas compared to previously used LGG-based regimens or radiotherapy. It also emphasizes the importance of a biopsy and a thorough molecular investigation of pontine lesions.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016440
- 003
- CZ-PrNML
- 005
- 20231026105824.0
- 007
- ta
- 008
- 231013s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00381-023-05976-3 $2 doi
- 035 __
- $a (PubMed)37165121
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Trkova, Katerina $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Pediatric Neurooncology Centre, University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
- 245 10
- $a DIPG-like MYB-altered diffuse astrocytoma with durable response to intensive chemotherapy / $c K. Trkova, D. Sumerauer, L. Krskova, A. Vicha, M. Koblizek, T. Votava, V. Priban, M. Zapotocky
- 520 9_
- $a Pontine gliomas represent difficult to treat entity due to the location and heterogeneous biology varying from indolent low-grade gliomas to aggressive diffuse intrinsic pontine glioma (DIPG). Making the correct tumor diagnosis in the pontine location is thus critical. Here, we report a case study of a 14-month-old patient initially diagnosed as histone H3 wild-type DIPG. Due to the low age of the patient, the MRI appearance of DIPG, and anaplastic astrocytoma histology, intensive chemotherapy based on the HIT-SKK protocol with vinblastine maintenance chemotherapy was administered. Rapid clinical improvement and radiological regression of the tumor were observed with nearly complete remission with durable effect and excellent clinical condition more than 6.5 years after diagnosis. Based on this unexpected therapeutic outcome, genome-wide DNA methylation array was employed and the sample was classified into the methylation class "Low-grade glioma, MYB(L1) altered." Additionally, RT-PCR revealed the presence of MYB::QKI fusion. Taken together, the histopathological classification, molecular-genetic and epigenetic features, clinical behavior, and pontine location have led us to reclassify the tumor as a pontine MYB-altered glioma. Our case demonstrates that more intensive chemotherapy can achieve long-term clinical effect in the treatment of MYB-altered pontine gliomas compared to previously used LGG-based regimens or radiotherapy. It also emphasizes the importance of a biopsy and a thorough molecular investigation of pontine lesions.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 12
- $a nádory mozkového kmene $x diagnostické zobrazování $x farmakoterapie $x genetika $7 D020295
- 650 12
- $a astrocytom $x diagnostické zobrazování $x farmakoterapie $x genetika $7 D001254
- 650 12
- $a gliom $x diagnostické zobrazování $x farmakoterapie $x genetika $7 D005910
- 650 _2
- $a histony $x genetika $7 D006657
- 650 _2
- $a pons $x patologie $7 D011149
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sumerauer, David $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Pediatric Neurooncology Centre, University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
- 700 1_
- $a Krskova, Lenka $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Pediatric Neurooncology Centre, University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
- 700 1_
- $a Vicha, Ales $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Pediatric Neurooncology Centre, University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
- 700 1_
- $a Koblizek, Miroslav $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Pediatric Neurooncology Centre, University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic
- 700 1_
- $a Votava, Tomas $u Department of Pediatrics, University Hospital in Pilsen, Alej Svobody 80, Pilsen-Lochotin, 323 00, Czech Republic
- 700 1_
- $a Priban, Vladimir $u Department of Neurosurgery, University Hospital in Pilsen, Alej Svobody 80, Pilsen-Lochotin, 323 00, Czech Republic
- 700 1_
- $a Zapotocky, Michal $u Prague Brain Tumor Research Group, Second Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic. michal.zapotocky@fnmotol.cz $u Pediatric Neurooncology Centre, University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic. michal.zapotocky@fnmotol.cz $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University Prague and University Hospital Motol, V Uvalu 84, 15006, Prague 5, Czech Republic. michal.zapotocky@fnmotol.cz
- 773 0_
- $w MED00002135 $t Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery $x 1433-0350 $g Roč. 39, č. 9 (2023), s. 2509-2513
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37165121 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105818 $b ABA008
- 999 __
- $a ok $b bmc $g 2000138 $s 1202802
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 39 $c 9 $d 2509-2513 $e 20230511 $i 1433-0350 $m Child's nervous system $n Childs Nerv Syst $x MED00002135
- GRA __
- $a 204220 $p Grantová Agentura, Univerzita Karlova
- GRA __
- $a PRIMUS/19/MED/06 $p Grantová Agentura, Univerzita Karlova
- GRA __
- $a LX22NPO5102 $p The project National Institute for Cancer Research (Programme EXCELES)
- GRA __
- $a MH CZ-DRO,00064203 $p University Hospital Motol
- LZP __
- $a Pubmed-20231013
